Vaccine最新文献

{"title":"Letter to the Editor: Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates.","authors":"Yung-Ching Lin","doi":"10.1016/j.vaccine.2025.127533","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.127533","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"127533"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring COVID-19 vaccination behavior: A cross-country study among pregnant and postpartum women in Brazil, Ghana, Kenya, and Pakistan.","authors":"Rupali J Limaye, Berhaun Fesshaye, Emily S Miller, Prachi Singh, Saleem Jessani, Muhammad Asim, Ferdinand Okwaro, Caroline Dinam Badzi, Emefa Modey Amoah, Renato T Souza, Maria Laura Costa, Sarah Saleem, Marleen Temmerman, Kwasi Torpey, Jose G Cecatti, Vanessa Brizuela, Jessica L Schue","doi":"10.1016/j.vaccine.2025.127478","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.127478","url":null,"abstract":"<p><p>Pregnant women infected with SARS-CoV2 are more likely to be hospitalized and require ventilation, compared to non-pregnant women. Although the development of the COVID-19 vaccine was regarded as a scientific breakthrough among many, the pace of development in combination with delayed and unclear recommendations for maternal vaccination led to slower vaccine uptake among this population. We explored the decision-making process for COVID-19 vaccination among pregnant and postpartum women in four countries: Brazil, Ghana, Kenya, and Pakistan through 201 in-depth interviews. A grounded theory approach was used for analysis, and a socio-ecological framework was used to synthesize emerging themes. Four levels of influence on vaccine-related attitudes and behaviors were identified: individual, interpersonal, community, and policy. Risk perception and beliefs about vaccines safety were the primary individual-level factors identified. Risk perception of the disease was a common reason for vaccine acceptance, whereas lower risk perception emerged as a reason to not vaccinate. Vaccine safety concerns, for the pregnant woman herself, her pregnancy, and her baby were common across all countries. At the interpersonal level, the influence of the male partner and peers emerged across all countries. While participants identified the partner or spouse was most influential, they also discussed the limited impact the male partner had on decision-making, particularly in Ghana, Kenya, and Pakistan. At the community-level, healthcare providers helped in allaying vaccine safety concerns, and women looked to them for their health expertise and recommendations. At the policy-level, the requirement - real or perceived - of vaccination to access services, travel, work, and education was an important factor in all countries. Vaccine decision-making is complex, multi-faceted, and context-specific. When promoting vaccination among pregnant and postpartum women, engaging influential individuals can support the successful uptake of maternal vaccination.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"127478"},"PeriodicalIF":0.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine attitudes and behaviors among pregnant women in Nairobi, Kenya with diverse socio-economic and educational backgrounds.","authors":"Jessica L Schue, Ferdinand Okwaro, Ingrid Gichere, Daizy Cherono, Mandeep Sura, Emily S Miller, Berhaun Fesshaye, Prachi Singh, Grace Belayneh, Rupali J Limaye, Marleen Temmerman","doi":"10.1016/j.vaccine.2025.127480","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.127480","url":null,"abstract":"<p><strong>Introduction: </strong>Pregnant women are at increased risk of severe manifestations of COVID-19, resulting in ICU admission, mechanical ventilation, and death compared to non-pregnant women. COVID-19 vaccines were approved for use in pregnant women in early 2022 by the World Health Organization, but permissive policies toward vaccine women differed by country. As education has been associated with vaccine uptake, this study sought to examine the association between socio-economic or educational status and vaccination behaviors, including reasons for vaccination or non-vaccination among pregnant women seeking health care services in Nairobi, Kenya.</p><p><strong>Methods: </strong>This study administered a survey to pregnant women at the two referral hospitals in Nairobi: Aga Khan University Hospital (AKUH) and Pumwani Maternity Hospital (PMH).</p><p><strong>Results: </strong>A total of 400 women took the survey. Pregnant women with college level education were more likely to have been vaccinated for COVID-19 compared to pregnant women without a college education. Women registered or visiting for pregnancy and delivery care from AKUH Kenya were also more likely to be vaccinated compared to women receiving care from PMH. Despite this difference in COVID-19 vaccine uptake, women from both the hospitals had similar reasons for receiving or refusing a COVID-19 vaccine. a Our findings align with previous studies that have showed that education status correlates positively with COVID-19 vaccination among pregnant women.</p><p><strong>Discussion: </strong>To improve maternal vaccination acceptance, education status can be used as a way to segment audiences to inform messaging and other demand generation efforts.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"127480"},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144628467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing attitudes toward COVID-19 vaccine decision making among pregnant women in Pakistan.","authors":"Saleem Jessani, Muhammad Asim, Sarah Saleem, Sidrah Nausheen, Haleema Yasmeen, Jessica L Schue, Prachi Singh, Sami L Gottlieb, Rupali J Limaye","doi":"10.1016/j.vaccine.2025.127479","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.127479","url":null,"abstract":"<p><strong>Background: </strong>Lower rates of COVID-19 vaccination among pregnant women prompt an investigation into the underlying reasons. This study aims to explore the attitudes of pregnant women in Pakistan regarding COVID-19 vaccination decision-making and to identify the factors influencing their vaccine uptake.</p><p><strong>Methods: </strong>A cross-sectional survey of pregnant women was conducted at two hospitals in Karachi in February-May 2024. The survey included a four-point Likert scale to evaluate 19 attitudes toward COVID-19 vaccination during pregnancy. These attitudes were later grouped into nine categories: disease risk perception, vaccine effectiveness, vaccine safety, general hesitancy (including concerns about vaccine ingredients), self-efficacy, social norms and family norms. Multivariable logistic regression was performed to identify attitudes associated with vaccine uptake.</p><p><strong>Results: </strong>Among the 400 women surveyed, 46 % (95 %CI: 41-51) reported being vaccinated against. COVID-19. Participants with higher COVID-19 risk perception were 5.71 times more likely to be vaccinated than their counterparts (95 %CI: 2.65-12.29). Those with higher self-efficacy and those who believed their friends or family had received or would receive the vaccine, had 2.28 (95 %CI: 1.08-4.65) times and 2.19 (95 %CI: 1.03-4.65) times higher odds of being vaccinated, respectively. The adjusted odds ratio for general vaccine hesitancy was 0.37 (95 %CI: 0.18-0.78), indicating that women with higher hesitancy were 63 % less likely to be vaccinated compared to those with lower hesitancy. Furthermore, women with less support from family regarding vaccine decision-making were 69 % less likely to be vaccinated than those who received more support.</p><p><strong>Conclusion: </strong>Attitudes associated with increased vaccination among pregnant women were higher COVID-19 risk perception, higher self-efficacy, and supportive social norms. In contrast, general vaccine hesitancy, and unsupportive family norms were significant barriers to vaccination during pregnancy. Targeted strategies are needed to address women's concerns about vaccine ingredients and promote supportive family influences, enhancing vaccine uptake in this important group.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"127479"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells\" [Vaccine 21(17-18) (2003) 1989-1994].","authors":"Motoharu Abe, Syoji Kuzuhara, Yoichiro Kino","doi":"10.1016/j.vaccine.2025.127426","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.127426","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127426"},"PeriodicalIF":0.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric virus-like particles replacing the loop on the surface of VP60 from rabbit hemorrhagic disease virus (RHDV) provide protection against two serotypes of RHDV.","authors":"Wangzhen Xiang, Beibei Pan, Yuxin Hao, Fei Wang, Jialu Bao, Shanchun Su, Shuai Qie, Chungang Pan, Zhen Cao, Xinyue Liu, Jiajun Wu, Tong Zhang, Xinyan Zhai, Fei Yang, Peng Qi, Jiangtao Wang, Jin Xiao, Xin Guo","doi":"10.1016/j.vaccine.2025.127427","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.127427","url":null,"abstract":"<p><p>In recent years, the rabbit hemorrhagic disease virus 2(RHDV GI.2) has rapidly spread worldwide due to its broad natural host range, strong pathogenicity, and significant antigenic differences from the traditional RHDV1 (GI.1). The widespread prevalence of both GI.1 and GI.2 RHDV poses a serious threat to the healthy development of the global rabbit industry. Despite this, there is still a notable absence of effective multivalent or broad-spectrum vaccines for controlling RHD(GI.1 and GI.2). In the present study, we developed a broad-spectrum chimeric antigen vaccine using a substitution strategy targeting the surface loop of the main antigen protein VP60 of RHDV. The chimeric VP60 antigen, expressed by a recombinant baculovirus expression system, was successfully assembled into virus-like particles (VLPs). The VLPs exhibited typical natural virus size and morphology under an electron microscope. Immunization with chimeric VLPs effectively protected rabbits from lethal challenged by both virulent strains of RHDV, GI.1 and GI.2, showing an effect comparable to that of a mixture vaccine containing two wild-type VLPs. These findings demonstrate a promising strategy for developing a cost-effective and straightforward preparation process for broad-spectrum vaccine against RHD.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127427"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunogenicity and safety of sequential Sabin strain inactivated poliovirus vaccine from different manufacturers in infants: Randomized, blinded, controlled trial.","authors":"Lei Wang, Weixian Han, Dan Li, Siquan Wang, Zhao Jiang, Yuwei Li, Siliang Zhou, Yongli Xiong, Yanfei Chen, Lixian Wang, Yingchao Wan, Jing Li, Yeqing Tong","doi":"10.1016/j.vaccine.2025.127448","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.127448","url":null,"abstract":"<p><strong>Objectives: </strong>The National Immunization Program allows using a different manufacturer's vaccine for follow-up doses when the same vaccine is unavailable. This study aimed to evaluate the safety and immunogenicity of administering a third dose of Sabin strain (sIPV) from a different manufacturer in infants who had previously received two doses of sIPV.</p><p><strong>Methods: </strong>This randomized, blinded, controlled trial enrolled 200 healthy infants (≤12 months) to assess the safety and immunogenicity of sequential vaccination, who were randomly assigned to receive a third dose of sIPV from either a different manufacturer (experimental group) or the same manufacturer as the first two doses (control group). The study took place in Xiaogan City, Hubei Province, China, from 20 May 2024 to 6 September 2024. Immunogenicity and safety were assessed using per-protocol and safety populations, respectively.</p><p><strong>Results: </strong>The seroconversion rates for poliovirus types 1, 2, and 3 were 79.52 %, 67.47 %, and 74.70 % in the experimental group, respectively, compared to 73.56 %, 49.43 %, and 63.22 % in the control group, with P-values of 0.360, 0.017, and 0.106, respectively. The most common systemic adverse event (AE) was fever, and no significant differences in the incidence of AEs between the two groups were observed. No serious adverse events related to vaccines were reported.</p><p><strong>Conclusion: </strong>Sequential vaccination with sIPV from different manufacturers demonstrated superior immunogenicity compared to the initial vaccine, with no significant safety differences, indicating that using vaccines from different manufacturers for sequential dosing is a feasible and effective option.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127448"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144565604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201.","authors":"Anna R Giuliano, Anna Beltrame, Luisa L Villa, Eduardo Lazcano-Ponce, Jorge Santana-Bagur, Betania Allen-Leigh, Alejandra J Portillo-Romero, Vikrant V Sahasrabuddhe, Margaret G House, Emma Brofsky, Lenice Galan de Paula, Roberto Carvalho da Silva, Michael J Schell, Julie Rathwell, Kimberly Isaacs-Soriano, Wenyi Fan, Caique Mello, Grant B Ellsworth, Timothy Wilkin","doi":"10.1016/j.vaccine.2025.127447","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.127447","url":null,"abstract":"<p><p>HPV-related oropharyngeal squamous cell carcinoma (OPSCC) has increased significantly among men, especially among men living with HIV. HPV vaccines have proven efficacy in preventing persistent anogenital HPV infections. However, less is known regarding vaccine efficacy against persistent oral HPV infection, the obligate precursor of OPSCC. In 2020, the 9-valent HPV (9vHPV) vaccine received accelerated approval from the FDA for the indication of prevention of HPV-related OPSCC and other head and neck cancers, pending confirmation of clinical benefit in further trials. Currently a Phase III trial is ongoing to evaluate efficacy of the 9vHPV vaccine in preventing persistent oral HPV infection in immunocompetent men (NCT04199689); however, no trials have been conducted in people living with HIV. Here we describe the rationale, design, and study population characteristics of the first randomized (1:1), double-blind, placebo-controlled trial evaluating the efficacy and immunogenicity of the 9vHPV vaccine in preventing persistent oral HPV infection in men aged 20-50 living with HIV. The primary objective is to demonstrate that the 9vHPV vaccine when given in a 3-dose regimen (Day 1, Months 2 and 6) reduces the incidence of persistent (≥6 months) oral HPV infection with 9vHPV vaccine types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in men living with HIV who are oral HPV negative to the relevant HPV type at enrollment, compared with placebo. The trial began in February 2021 and completed enrollment of 700 men at clinical sites in Brazil, Mexico, and Puerto Rico in February 2024. The secondary objectives are to evaluate the vaccine-induced serum anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 responses, and the safety and tolerability of the 9vHPV vaccine in men living with HIV. Results from this study may inform policy regarding vaccination strategies for people living with HIV. ClinicalTrials.gov Identifier: NCT04255849.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127447"},"PeriodicalIF":0.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral vaccination with live Mycoplasma pneumoniae elicits a respiratory protective immunity in a murine model.","authors":"Lan Yu, Chunyan Chen, Guiting He, Yan Meng, Huanbing Long, Jiarong He, Shuihong Li, Cuiming Zhu","doi":"10.1016/j.vaccine.2025.127460","DOIUrl":"https://doi.org/10.1016/j.vaccine.2025.127460","url":null,"abstract":"<p><p>Vaccine development targeting Mycoplasma pneumoniae began in the 1960s, but achieving safe and effective immunization is still challenging. Careful consideration of the immunization pathway is one of the critical aspects of vaccine development. In this investigation, C57BL/6 J mice were intragastrically vaccinated with live M. pneumoniae, and the short-term safety and resultant immune effects were evaluated. Oral administration likely demonstrated intestinal clearance with restricted systemic dissemination and no tissue pathogenicity in both the intestinal and pulmonary tracts. Furthermore, the oral vaccination with live M. pneumoniae effectively reduced the pathogen burden in the lung, alleviated pulmonary inflammation, and reduced the pulmonary secretion of IL-1β and TNF-α after intranasal bacterial infection 3 or 15 weeks after the last dose. Moreover, Airway exposure to M. pneumoniae in live pathogen intragastric vaccinated mice triggered robust recall responses, marked by the elevation of systemic mycoplasma-specific IgG and IgM, alongside pulmonary mucosal IgA, paralleled by clonal expansion of Th1, Th2, and CTL. In conclusion, oral delivery presents a promising route for developing M. pneumoniae vaccines.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127460"},"PeriodicalIF":0.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older.","authors":"Shoroq M Altawalbeh, Angela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, Lee H Harrison, William Schaffner, Richard K Zimmerman, Kenneth J Smith","doi":"10.1016/j.vaccine.2025.127433","DOIUrl":"10.1016/j.vaccine.2025.127433","url":null,"abstract":"<p><p>A 24-valent pneumococcal conjugate vaccine (PCV24) is currently in development and could potentially be used in all adults aged 50 years and older. This study evaluated risk- and age-based PCV24 use to ascertain its potential public health effects, budget impact, and cost-effectiveness. A Markov decision analysis model compared PCV24 and all currently recommended pneumococcal vaccines. Age-based vaccination could occur at age 50 or at ages 50 and 65. The analysis separately examined hypothetical cohorts of U.S. Black and non-Black individuals with and without consideration of childhood pneumococcal vaccination indirect effects, using race-specific pneumococcal disease and vaccination data. Cohorts were tracked over a lifetime horizon from both societal and healthcare perspectives. Model parameters were derived from U.S. data and parameter uncertainty was evaluated through deterministic and probabilistic sensitivity analyses. Budgetary impact of 21-valent conjugate vaccine (PCV21), PCV24, and combinations of both at different ratios was also assessed. From societal and healthcare perspectives, PCV24 prevented fewer pneumococcal disease cases and deaths but was less economically favorable than strategies using PCV21. Other vaccines were similarly less favorable than PCV21. When adding childhood vaccination indirect effects, PCV24 strategies remained unfavorable compared to PCV21 strategies. In probabilistic sensitivity analyses, PCV21 at ages 50 and 65 was preferred in 99 % of model iterations for Black cohorts and 85 % for non-Blacks at a $100,000/QALY willingness-to-pay threshold. Budget impact for PCV24 and PCV21 were not substantially different but PCV21 prevented more hospitalizations and deaths. Compared to PCV21, which is formulated solely on adult pneumococcal epidemiology, PCV24 and other childhood epidemiology-formulated vaccines were less economically favorable among adults aged 50 and older. Budget impacts of PCV21 and PCV24 use were similar.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"61 ","pages":"127433"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}